

## HEADLINES

### **Kenneth Pienta, M.D., Is New Associate Dean for Clinical and Translational Research**

The University of Michigan Board of Regents recently approved the appointment of Kenneth J. Pienta, M.D., as Associate Dean for Clinical and Translational Research at the University of Michigan Medical School and Director of the Michigan Institute of Clinical and Health Research (MICHHR).

"Dr. Pienta is already a valued member of the U-M team," says Steven L. Kunkel, Ph.D., Senior Associate Dean for Research. "As an accomplished physician scientist whose research career has spanned the entire translational research continuum, from basic science discovery to patient care, Dr. Pienta is ideally suited to lead MICHHR and assist me in creating a common vision for clinical and translational research at Michigan."

Dr. Pienta is a Professor of Internal Medicine and Urology; Director, Urologic Oncology Program, U-M Comprehensive Cancer Center; and Director, Experimental Therapeutics for the Michigan Center for Translational Pathology. He is also affiliated with the Cellular and Molecular Biology Program and the Center for Computational Medicine and Biology.

Since 1995, Dr. Pienta has been the Director of the U-M Prostate Specialized Program of Research Excellence. He has a proven, peer-reviewed track record in developing a translational research program that successfully incorporates bench research, agent development, and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer. His endeavors in translational research led to the first ever American Association for Cancer Research Team Science Award. As chairman of the Translational Medicine Committee of the Southwest Oncology Group, he is responsible for incorporating the paradigm of translational medicine into clinical trials.

Dr. Pienta is the author of more than 250 peer-reviewed articles and has been the principal investigator on numerous local and national clinical trials. He has a significant clinical presence as an internationally recognized clinician in prostate cancer, as well as being recognized for his development of a "rapid autopsy" program to collect metastatic prostate cancer tissue. He is currently involved in research to define the tumor microenvironment of prostate cancer metastases, as well as developing new therapies for prostate cancer.

In 2005, Dr. Pienta was elected to the American Society of Clinical Investigation. He is a two-time American Cancer Society Clinical Research Professor Award recipient, and he serves on the Boards of the Paget Foundation, Bone and Cancer Foundation, and Southwest Oncology Group.

Dr. Pienta is a graduate of the Johns Hopkins School of Medicine. He completed his internal medicine residency at the University of Chicago and his medical oncology fellowship at Johns Hopkins University. He was an Assistant Professor of medicine at the Wayne State University School of Medicine from 1991-1994. Dr. Pienta joined the University of Michigan in 1994 as an Associate Professor of medicine and surgery.

### **Office of Research Welcomes Joan Keiser, Ph.D.**

Senior Associate Dean Steven L. Kunkel, Ph.D., is pleased to announce that Joan Keiser, Ph.D., FAHA, has joined the Office of Research from a 20 year career with Park Davis and Pfizer Global Research and Development. At Pfizer, Dr. Keiser was Vice President for Cardiovascular and Metabolic Diseases research overseeing a portfolio of discovery and early clinical drug discovery projects from five research sites around the world.

Dr. Keiser's ties to the University of Michigan Medical School began in 1978 when she joined the Ph.D. program in Physiology. She reestablished ties with the University in 1994 when she joined the faculty as an Adjunct Professor of Physiology. For the last eight years, Dr. Keiser has taught in the Medical School M1 curriculum. Her role in the Office of Research involves research strategic planning. Please join us in welcoming Dr. Keiser to the Office of Research.

### **Electronic Routing and Proposal Management (eRPM) is Coming!**

Many faculty and staff are aware that all of campus is moving to an electronic routing and approval process for sponsored projects. By late Spring, the Health System will be using the new eRPM (Electronic Routing and Proposal Management) system to route proposals. eRPM also posts all project award documents (PANs and PACs) – creating an electronic file of all official award paperwork.

In February 2009, there will be two large-scale, lecture-style information sessions to give any interested faculty and staff an overview of the eRPM system along with an introduction to the required business process changes within the Medical School and Hospital. Jim Randolph from DRDA/MAIS and Heather Offhaus from the Medical School Grant Review & Analysis Office will be presenting. Both sessions will have the same content and are scheduled for:

Wednesday, February 11, 2009

1:00 - 3:00 PM  
3330 Med Sci I

Thursday, February 12, 2009

9:00 - 11:00 AM  
3330 Med Sci I

Please register to attend a session online at ([http://cgi.research.umich.edu/training/research/research\\_training\\_dates.lasso?desc\\_id=297](http://cgi.research.umich.edu/training/research/research_training_dates.lasso?desc_id=297)).

In addition to this opportunity, you are invited and encouraged to visit the eRPM Sandbox and test the look and feel at your leisure. In the Sandbox you may create proposals (test versions only – do not use the system for real projects at this point), practice uploading documents, and try out the features of downloading a federal opportunity and form set through the system. You may access the Sandbox through the eResearch site on the web (<http://www.umich.edu/~eresinfo/erpm/sandbox.html>).

For those that would like hands-on training in a small setting (in addition to the overview and business process discussion), there will be several opportunities for Health System faculty and staff in the Taubman Library. The sessions will be led by eRPM trainers from MAIS. You may register through the web at ([http://cgi.research.umich.edu/training/research/research\\_training\\_dates.lasso?descr\\_id=303](http://cgi.research.umich.edu/training/research/research_training_dates.lasso?descr_id=303)).

Finally, if you would like the history and information about the eRPM project, please visit (<http://www.umich.edu/~eresinfo/pm.html>).

The Health System's Unit Liaison for this project is Heather Offhaus in the Grant Review & Analysis Office. Feel free to contact Heather at ([hmills@umich.edu](mailto:hmills@umich.edu)) or 734-763-4272 with any questions about the system, training, or related information.

### **BMRC New Initiatives Fund to Support Basic Science Research**

**Deadline: February 16, 2009**

The Medical School's Biomedical Research Council (BMRC) is accepting applications to a New Initiatives funding program to support high-quality scientific projects of a primarily basic science nature that are specifically aimed at applying innovative ideas or technology to longstanding problems of critical biomedical importance. For more details about the program and eligibility requirements, please visit the website (<http://www.med.umich.edu/medschool/research/support/funding/newinitiatives.htm>). If there are questions about the information on the website, please contact Camille Mrozowski in the Office of Research at 734-615-8802 or ([cmrozow@umich.edu](mailto:cmrozow@umich.edu)).

## **RESEARCH COMPLIANCE TRAINING AND EDUCATION**

### *Human Research*

#### **Information for Device Researchers and Developers**

Most seasoned investigators are aware that federal regulations prohibit commencing research involving human subjects until after an IRB has approved the study or has determined it is exempt. A problem the IRB occasionally encounters is that device investigators know the definitions of "human subjects" and "research" as written in the federal regulations known as the "Common Rule," 45 CFR 46 subpart A, but not as defined in the Food and Drug Administration's (FDA) device regulations.

The **Common Rule** defines a "Human Subject" as: "[A] living individual about whom an investigator . . . conducting research obtains: (1) Data through intervention or interaction

with the individual, or (2) Identifiable private information" (45 CFR 46.102[f]). It defines "Research" as: "[A] systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge."

In contrast, **FDA device regulations** use different definitions. "*Subject* means a human who participates in an investigation, either as an individual on whom or on whose specimen an investigational device is used or as a control . . ." 21 CFR 812.3 (p). Research is defined as "[A]ny experiment that involves a test article and one or more human subjects [or specimens]. . . the results of which are intended to be submitted to . . . FDA." 21 CFR 56.102 (c).

**What difference does this make for investigators developing new devices?** If we use the example of actual humans entering a trial, the difference in terms of IRB review is nil. However, if we are referring to **anonymized specimens** used in early phases of device development, the difference is significant.

Under the Common Rule using completely deidentified specimens would *not* require IRB review because the specimens do not qualify as "human subjects" because there is no "identifiable private information" associated with the specimens. But under **FDA device regulations**, the definition of both subjects and research are met if the investigator intends to submit to the FDA the scientific data obtained using the specimens. This data is often submitted to support an application for an "investigational device exemption" (IDE). *Therefore, this use requires IRB review and approval.*

For more information on this topic, contact us at ([irbmed@umich.edu](mailto:irbmed@umich.edu)) or see the FDA Guidance document titled "Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable" at (<http://www.fda.gov/cdrh/oivd/guidance/1588.pdf>).

### *Animal Research*

#### **Happy New Year from the UCUCA Office!**

- **Adding New Students to Protocols**

Please remember that any new students should be added to your protocol if they will be working with animals. In order to add new personnel, please send an email to the UCUCA Office ([ucuca.office@umich.edu](mailto:ucuca.office@umich.edu)) and provide the student's name and contact information, the UCUCA approved protocol number, and the principal investigator's name. Or log into eSirius and select "Submit an amendment to an approved protocol."

- **Vaporizer Use**

As a result of the recent Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) site visit, the UCUCA office now needs to be notified of the existence of vaporizers and the last date the machine underwent the required yearly maintenance. If your laboratory uses a vaporizer and has not already responded to our emailed survey, please contact the UCUCA office so that we may add you to our database. In addition, ULAM has arranged to have a service technician visit campus twice yearly to service anesthetic machines and vaporizers and can arrange to

*Biomedical News • January 2009*

provide service to your machine at that time. Machines are required to undergo at least yearly maintenance as required by the "UM Program for Monitoring Anesthetic Machines and Vaporizers." Please feel free to contact the UCUCA Office at 734-763-8028 or ([ucuca.office@umich.edu](mailto:ucuca.office@umich.edu)) if you have any questions or concerns.

#### • **Training**

Animal care training is based on regulatory requirements (Public Health Service Policy and the Animal Welfare Act) and the commitment of the University of Michigan to ensure that animal research performed here is done in the most humane and effective manner. As the animal research program has grown over the years, it has become necessary to increase staff and develop new ways of providing support to animal users. In order to improve the utilization of training resources, increase the coordination of training activities and messages, and reduce redundancy in training, all of the training provided by ULAM and UCUCA has been combined into a centralized unit. To this end, the ULAM Training Core has been created. By having trainers from each area work together, we plan to improve the consistency and availability of courses offered to all of our customers.

The training core offices and wet lab have moved from the North Ingalls Building (NIB) to the Life Sciences Institute Building (LSI). Training will be coordinated through the Training Core rather than the UCUCA office.

#### **Training Core Offices**

Location: 1016 LSI

Phone: 734-763-8039

Email: [ulamtraining@umich.edu](mailto:ulamtraining@umich.edu)

Website: <http://www.ulam.umich.edu/training.htm>

#### **Staff Structure**

Faculty Supervisor: Melissa Dyson, DVM, MS, DACLAM

Research Staff Training Specialist: Melissa Rogers, LVT

Clinical Training Specialist: Lori Roberts, LVT, LAT

Husbandry Training Specialist: Daphne Molnar BS, CMAR, RLATg

Husbandry Trainers: Chris Mannor, BS, LAT and Shelly Yakich, LAT

## **FREQUENTLY ASKED QUESTIONS**

The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (<http://www.med.umich.edu/medschool/research/faq.htm>).

### **Q) When should I submit my study to the Clinical Research Billing Unit (CRBU)?**

**A)** As soon as you believe you have good drafts of your study documents including the protocol, informed consent, budgets (internal and external), and clinical trial agreements/grants, you should submit to the CRBU. You should not wait until you have IRBMED approval and DRDA approval to submit to the CRBU. Any documents you think are good enough to submit to IRBMED and DRDA will be good enough for the CRBU to do an analysis.

### **Q) How do I initiate the clinical research billing review?**

**A)** To initiate the clinical research billing review, the study team must provide several documents to the Clinical Research Billing Unit (CRBU). The required documents are the protocol, consent, and a billing calendar. If the study has any sponsors, budgets (internal and external) and agreements/grants should also be provided. The documents can be the draft versions the study team believes are final. IRB and DRDA approvals of the documents are not required for them to be provided to the CRBU. The CRBU review should take place at the same time as these other reviews. All documents should be sent to the CRBU at ([CRB-Unit@umich.edu](mailto:CRB-Unit@umich.edu)). Any questions about the process can be sent to this email address or the CRBU can be contacted at 734-998-6880.

## **KUDOS**

### **Cassandra Wong Receives Lamar Houston Award**

The Executive Board of the National Association of Scientific Materials Managers (NAOSMM) implemented a new award to honor individuals whose service to NAOSMM is beyond the category of outstanding or exceptional. The Lamar Houston Award is named in honor of the NAOSMM founder who had the inspiration to establish the association in 1974.

Cassandra Wong, who is now Director of the Biomedical Research Core Facilities, was the recipient of the first Lamar Houston Award presented at the 35th Annual Conference and Trade Show. Ms. Wong has been the Trade Show Coordinator for NAOSMM for many years and has contributed innumerable hours of her time to make the trade show work each year. She has done so without a proper committee to assist her but still fulfilled the duties of the most heavily tasked committee in NAOSMM. The exhibitors and members owe a great deal of gratitude to her for her organizational skills, desire and dedication. Cassandra Wong personifies the spirit of the award, the dedication that the founder of NAOSMM established, and is a very worthy recipient of the Lamar Houston Award. Please join us in congratulating Ms. Wong.

## **FUNDING/AWARD OPPORTUNITIES**

Funding opportunities listed below are for external limited submissions and opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (<http://www.med.umich.edu/medschool/research/support/funding.htm>). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

### *External Limited Submissions*

These are opportunities in which the sponsor has limited the number of proposals allowed from an institution. These competitions require an internal review to select the proposals to submit to the sponsor from the University of Michigan.

Abstracts listed here are general information about these funding programs. We strongly urge interested applicants to visit



the listed website to verify complete eligibility, program information, and application procedures before submitting an application.

### **Dana Foundation Program in the Neuroimmunology of Brain Infections and Cancers**

**Internal Deadline: February 11, 2009**

The Dana Foundation Neuroimmunology Program invites proposals focusing on brain infections and cancers. Specifically, they are inviting studies of (1) immune-based therapies for primary brain tumors and for metastases to the brain of other cancers; (2) immune responses to infections in the brain, including but not limited to viral encephalitis, meningitis, cerebral malaria, and prion diseases; and (3) how immune functions are carried out and modified in the brain. Some examples of the areas of focus are:

- Exploring ways to stimulate immune cell recognition and attack of primary brain tumors and metastases.
- Measuring responses to therapeutic vaccines or other immunotherapies for treating brain tumors.
- Determining ways to prevent and defend against viral infections in the brain.
- Examining ways to treat infections in the brain, including cerebral malaria.
- Characterizing the roles of immune cells in normal brain and how these functions are modified under abnormal brain conditions.

Projects involving collaborations with NIH intramural researchers or industry scientists are acceptable. The Foundation will provide grants totaling up to \$200,000 payable over three years.

**The UM Medical School may submit one proposal for this grant program.** Deadline for submission of an application to the foundation is April 1, 2009. **This program focuses on providing support to faculty tenure track researchers early in their career, at the assistant professor level, or early in their associate professor career. Established researchers pioneering efforts in brain infections and cancers, however, are also eligible to apply. Postdoctoral fellows are not eligible.**

For consideration as an institutional nominee, submit the following electronically in a single PDF document by **February 11, 2009** to ([limitedsubmissions@umich.edu](mailto:limitedsubmissions@umich.edu)): a 3-page research plan, a NIH formatted biosketch, and a nominating letter from the department chair. **We acknowledge receipt of all electronic submissions. If you do not receive a response from us by the end of the next business day, please call us at 734-763-4086.** Contact Kathryn Ridner at 734-763-4086 or ([kridner@umich.edu](mailto:kridner@umich.edu)) with any questions. Visit the Dana website (<http://www.dana.org/grants/neuroimmunology>) for more information.

### **David and Lucile Packard Foundation Fellowships for Science and Engineering**

**Internal Deadline: February 13, 2009**

**(Nominees identified to Foundation by March 16, 2009)**

**Foundation Deadline: April 20, 2009**

The intent of the Fellowship Program is to provide support for unusually creative researchers early in their careers and to emphasize support for innovative individual research that involves the Fellows, their students, and junior colleagues,

rather than extensions or components of large-scale, ongoing research programs.

**Eligible candidates: Candidates must be faculty members** who are eligible to serve as principal investigators engaged in research in the natural and physical sciences or engineering **and must be within the first three years of their faculty careers.** That is, whose initial faculty appointments began no earlier than May 31, 2006, and no later than May 31, 2009.

Disciplines that will be considered include physics, chemistry, mathematics, biology, astronomy, computer science, earth science, ocean science, and all branches of engineering. Candidates engaged in research in the social sciences will not be considered. The awards provide individual grants of \$875,000 distributed over five years.

**The University of Michigan has been invited to nominate two faculty members.** For consideration as an institutional nominee, submit the following **electronically in a single document to ([OVPRlimitedsubmissions@umich.edu](mailto:OVPRlimitedsubmissions@umich.edu)) by February 13, 2009:**

1. Nomination letter from dean or department chair.
2. 1-2 page research statement responsive to the RFP, describing why the research is important and outlining the general goals for the next five years.
3. NIH formatted biosketch.
4. **Names only** of three external references, including at least one of a person who has had no supervisory or collaborative contact with the nominee.

The University's nominees will be notified promptly of their selection and must then prepare and submit their completed applications to the Packard Foundation by April 20, 2009. Additional information and guidelines for preparation are posted on the Foundation website (<http://www.packard.org/genericDetails.aspx?RootCatID=3&CategoryID=152>).

Please contact Jane Ritter ([ritterj@umich.edu](mailto:ritterj@umich.edu) or 734-763-1290) with questions regarding this fellowship program. Further information on this and other current funding opportunities may be obtained at (<http://www.research.umich.edu/>) – look for the “Limited Submissions” link under “Popular Links.”

### *Internal Submissions*

#### **UM Research Partnership Program**

**Deadline: February 2, 2009**

The Research Partnership Program includes the following funding opportunities available to faculty and graduate students. To obtain guidelines and application forms, visit ([http://www.research.umich.edu/funding/um\\_sources/rpp.html](http://www.research.umich.edu/funding/um_sources/rpp.html)).

- **The Spring/Summer Research Grants Program** will award a maximum of 40 grants to faculty to enable them to hire doctoral students to assist with their research and scholarly projects while providing both financial support and tasks of intellectual benefit to participating doctoral students. In addition, there will be two Sokol Grants for Faculty and Graduate Student Research Projects in the Sciences awarded as a part of this program.
- **The Distinguished Faculty and Graduate Student Seminars Program** will provide a maximum of five awards to groups of faculty, students or graduate

*Biomedical News* • January 2009

programs proposing innovative seminars and colloquia to foster collaboration and stimulate new research. Awards will range from \$5,000 to \$10,000 and may be used to complement funds from department, college or external sponsors.

### **UM Geriatrics Center Biology of Aging Pilot Grant Competition**

**Deadline: February 6, 2009**

The University of Michigan Geriatrics Center announces the availability of funds to support pilot/feasibility research in the Biology of Aging. Funding is provided by the National Institute on Aging via the Nathan Shock Center for the Basic Biology of Aging, directed by Dr. Richard Miller. The Pilot Grant competition is sponsored by the Center's Research Development Core, directed by Dr. Susan Brooks.

Proposals should address either fundamental questions in the genetics or cell and molecular biology of aging or mechanisms of aging in specific organ systems. **Only those with full-time faculty positions at the University of Michigan are eligible.** Most awards are made to junior faculty, but senior scientists are encouraged to apply if they are seeking support for new initiatives in aging research. Awards are for one year, not to exceed \$40,000, with funding available by July 1, 2009. A second year of funding may be requested on a competitive basis.

Applications can be obtained from the website (<http://sitemaker.umich.edu/nsc/home>) or by contacting Jane Heibel ([jheibel@umich.edu](mailto:jheibel@umich.edu) or 734647-1956).

### **Michigan Alzheimer's Disease Research Center (MADRC) Pilot Project Funding**

**Deadline: February 16, 2009 – 5:00 PM**

The Michigan Alzheimer's Disease Research Center (MADRC) invites members of the University of Michigan scientific community to submit an application for pilot project funding. The proposed research should be relevant to Alzheimer's disease and related dementias. Two projects will be funded for a period of one year, beginning 6/1/09 and ending 5/31/10. Two additional projects will be considered for funding beginning 6/1/10 and ending 5/31/2011. Each pilot project will receive \$35,000 in direct costs.

Applications must include the following NIH PHS 2590 forms: (A) Form Page 1: Face Page; (B) Form Page 2; (C) Form Page 4: Detailed Budget for Initial Budget Period; and (D) Biographical Sketch Format Page. The research description (Form Page 2) cannot be longer than 10 pages. Please fill these forms out in Microsoft Word format and submit them using Microsoft Word as well. These forms may be found at (<http://grants.nih.gov/grants/funding/2590/2590.htm>).

On Form Page 2 please include Specific Aims (Objectives), Background, Methods, and Relevance. We encourage everyone to apply, but applications received from junior investigators, established investigators who are new to Alzheimer's disease research, and investigators who have not previously received pilot project funding through the MADRC will be looked upon favorably. At the end of the funding period, the MADRC anticipates one or more publications and/or continued funding in the form of a new R01 or equivalent grant resulting from funded proposals.

Please email all final applications to ([clkenned@umich.edu](mailto:clkenned@umich.edu)). For questions please contact Courtney Kennedy at 734-615-8462 or ([clkenned@umich.edu](mailto:clkenned@umich.edu)). The website for the MADRC is (<http://www.med.umich.edu/alzheimers/>).

### **OVPR UM Research Faculty Awards**

**Deadline: February 20, 2009**

Research Faculty Awards recognize the important role research faculty play in the intellectual life and work of the University. For more information and nomination guidelines, visit (<http://www.research.umich.edu/contacts/ovpr/RFawards/>) or contact Jane Ritter at 734-763-1290 or ([ritterj@umich.edu](mailto:ritterj@umich.edu)).

- **Collegiate Research Professorship** – designed to recognize exceptional scholarly achievement and impact on advancing knowledge in science, engineering, health, education, the arts, the humanities or other academic fields of study. This award carries an annual stipend of \$2,000 for the initial five-year term.
- **Research Faculty Achievement Award** – designed to recognize outstanding scholarly achievements, as represented by significant contributions to an academic field of study over time, a specific outstanding discovery, or the development of innovative technology. (\$1,500)
- **Research Faculty Recognition Award** – designed to recognize exceptional scholarly achievements, as evidenced by publications and/or other scholarly activities in any academic field of study. (\$1,000)

### **Rackham UM Faculty Awards**

**Deadline: Various (see below)**

Several faculty awards are offered through the Rackham Graduate School. For complete details, visit ([http://www.rackham.umich.edu/faculty\\_staff](http://www.rackham.umich.edu/faculty_staff)).

- **Distinguished Faculty Achievement Awards**

**Deadline: February 20, 2009**

These awards honor senior faculty who have consistently demonstrated outstanding achievements in the areas of scholarly research and/or creative endeavors, teaching and mentoring of students and junior faculty, service and a variety of other activities which have brought distinction to themselves and to the University of Michigan. The award is \$1,500.

- **Faculty Recognition Awards**

**Deadline: February 20, 2009**

These awards are intended for faculty in the earlier phase of their careers who have demonstrated substantive contributions to the University through significant achievements in scholarly research and/or creative endeavors; excellence as a teacher, advisor and mentor; and distinguished participation in the service activities of the University. The award is \$1,000.

- **Distinguished University Professorships**

**Deadline: March 9, 2009**

The Distinguished University Professorships recognize exceptional scholarly and/or creative achievement, national and international reputation, and superior teaching skills. Each professorship carries with it an annual salary supplement of \$5,000 and an annual research supplement of \$5,000. The duration of the appointment is unlimited, and the title—without the

salary and research supplements—may be retained after retirement.

• • • *Deadline Watch* • • •

**OVPR Staff Service Awards Program**

**Deadline: January 23, 2009**

([http://www.research.umich.edu/contacts/ovpr/staff.awards/Nomination\\_guidelines.html](http://www.research.umich.edu/contacts/ovpr/staff.awards/Nomination_guidelines.html))

For questions, contact Jane Ritter at 734-763-1290 or ([ritterj@umich.edu](mailto:ritterj@umich.edu)).

**Distinguished Faculty Lectureship Award in Biomedical Research**

**Deadline: February 6, 2009**

(<http://www.med.umich.edu/medschool/faculty/facultyawards/facultylectureship.htm>)

Direct any questions to Camille Mrozowski at ([cmrozow@umich.edu](mailto:cmrozow@umich.edu)).

## UMMS AWARDED GRANTS

### *External Awarded Grants*

**Anesthesiology**

**PI:** Harris, Richard

**Co-I:** Clauw, Daniel (Anesthesiology Department)

**Title:** PREGABALIN ON BRAIN RESPONSE TO MECHANICAL PAIN AS ASSESSED BY FUNCTIONAL MAGNETIC RESONANCE IMAGING PROTON MAGNETIC RESONANCE SPECTROSCOPY AND SUBJECTIVE RATINGS (A DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER STUDY IN FIBROMYALGIA SUBJECTS TO EXAMINE EFFECTS OF)

**Sponsor:** Pfizer Incorporated

**Project Dates and Amount of Award:** 12/01/08-10/31/09; \$737,829

**PI:** Opp, Mark

**Title:** A MODEL FOR DELINEATING THE PATHOGENESIS OF CHRONIC FATIGUE

**Sponsor:** NIH - Subcontracts TO Southern Illinois University Medical School

**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$150,960

**Comprehensive Cancer Center**

**PI:** Pienta, Kenneth

**Title:** ISPORE RETREAT: JOHNSON AND JOHNSON, ORTHO BIOTECH ONCOLOGY RESEARCH & DEVELOPMENT AND UNIVERSITY OF MICHIGAN PROSTATE SPORE/GENITOURINARY ONCOLOGY PROGRAM EVALUATE PRECLINICAL AND CLINICAL COLLABORATION OPPORTUNITIES AND PROMISING SCIENTIFIC DISCOVERIES.

**Sponsor:** Centocor, Inc.

**Project Dates and Amount of Award:** 12/09/08-12/08/09; \$10,000

**PI:** Smith, David

**Title:** MDX-1106 IN SUBJECTS WITH SELECTED ADVANCED OR RECURRENT MALIGNANCIES (UMCC 2008.069 - A PHASE 1B, OPEN-LABEL, MULTICENTER, MULTIDOSE, DOSE-ESCALATION STUDY OF)

**Sponsor:** Medarex, Inc

**Project Dates and Amount of Award:** 12/01/08-12/31/11; \$1,603,023

**Emergency Medicine**

**PI:** Borgialli, Dominic

**Title:** EDUCATION PROGRAM ON PREHOSPITAL PEDIATRIC PAIN MANAGEMENT (A MULTI-CENTER STUDY TO EVALUATE THE EFFECT OF AN)

**Sponsor:** Health and Human Services, Department of Health Resources and Services Administration-Subcontracts TO University Of Texas Southwest H34 MC 11116

**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$34,281

**PI:** Scott, Phillip

**Title:** CARDIOVASCULAR HEALTH GRANT

**Sponsor:** CDC-Subcontracts TO MI, State Of Community Health

**Project Dates and Amount of Award:** 11/01/08-09/30/09; \$11,520

**Family Medicine**

**PI:** Fetters, Michael

**Title:** JAPANESE HEALTH EDUCATION AND MEDICAL EXCHANGE

**Sponsor:** Japan Business Society of Detroit Foundation

**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$4,000

**Internal Medicine**

**PI:** Baker, Laurence

**Title:** BIOLOGY OF PROSTATE CANCER PREVENTION TRIAL SUBCONTRACT

**Sponsor:** NIH - Subcontracts TO University of Texas

**Project Dates and Amount of Award:** 08/20/08-04/30/09; \$5,261

**PI:** Burant, Charles

**Co-I:** Byun, Jaeman (MI Metabolic & Obesity Ctr) / Das, Arun (MI Metabolic & Obesity Ctr)

**Title:** RECHARGE: METABOLOMICS CORE

**Sponsor:** Various Sponsors TO Medical University of Vienna

**Project Dates and Amount of Award:** 11/01/08-10/31/11; \$5,200

**PI:** Chan, Kevin

**Title:** ANTIVIRAL ACTIVITY OF AEROSOLIZED ALN-RSV01 PLUS STANDARD OF CARE IN LUNG TRANSPLANT PATIENTS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) (ALN-RSV01-106: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND)

**Sponsor:** Alnylam Pharmaceuticals TO Quintiles, Inc.

**Project Dates and Amount of Award:** 12/05/08-02/04/11; \$90,280

**PI:** Chen, Yuqing

**Title:** CRP BIOLOGY AND VASCULAR DISEASE

**Sponsor:** NIH 1 R01 HL 088391 01 A2

**Project Dates and Amount of Award:** 12/10/08-11/30/13; \$1,842,979

**PI:** Chetcuti, Stanley

**Title:** IMPELLA RECOVER LP 2.5 SYSTEM VERSUS INTRA AORTIC BALLOON PUMP (IABP) IN PATIENTS UNDERGOING NON-EMERGENT HIGH RISK PCI (PROTECT II: A PROSPECTIVE, MULTI-CENTER RANDOMIZED CONTROLLED TRIAL OF THE)

**Sponsor:** Abiomed Inc

**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$44,686

**PI:** Erba, Harry

**Title:** PROTEINASE 3 PR1 PEPTIDE MIXED WITH MONTANIDE ISA-51 VG ADJUVANT AND ADMINISTERED WITH GM-CSF IN ELDERLY PATIENTS WITH AML IN FIRST COMPLETE REMISSION OR ADULTS IN SECOND COMPLETE REMISSION: A PIVOTAL STUDY (UMCC 2008.038: A PHASE 3, RANDOMIZED, DOUBLE BLIND, MULTICENTER STUDY OF)

**Sponsor:** The Vaccine Company TO Ingenix Pharm Services

**Project Dates and Amount of Award:** 11/21/08-03/23/12; \$249,453

**PI:** Hussain, Maha

**Title:** UMCC 2008.033: A PHASE I/II TRIAL OF ABI-008 (NAB-DOCETAXEL) IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER

**Sponsor:** Abraxis BioScience, Inc.

**Project Dates and Amount of Award:** 12/08/08-12/07/11; \$110,073

**PI:** Kaul, Daniel

**Title:** CONVENTIONAL AND HIGH DOSE OSELTAMIVIR IN THE TREATMENT OF IMMUNOCOMPROMISED PATIENTS WITH INFLUENZA (A DOUBLE-BLIND, RANDOMIZED, STRATIFIED, MULTI-CENTER TRIAL EVALUATING)

**Sponsor:** Hoffmann-Laroche, Inc TO Quintiles, Inc.

**Project Dates and Amount of Award:** 12/19/08-09/30/10; \$36,742

**PI:** Keshamouni, Venkateshwar

**Title:** TARGETING TGF-BETA MEDIATED TUMOR-STROMAL INTERACTIONS IN LUNG CANCER

**Sponsor:** American Cancer Society

**Project Dates and Amount of Award:** 01/01/09-12/31/12; \$720,000

**PI:** Koch, Alisa

**Title:** FUNDING FOR RHEUMATOLOGY RESEARCH TRAINEES TO PRESENT DATA AT MEETINGS

**Sponsor:** Genentech, Inc.

**Project Dates and Amount of Award:** 10/24/08-10/23/09; \$7,500

**PI:** McMillan, Tracy

**Title:** TLR9 ACTIVATION AND FIBROTIC RESPONSES IN ALVEOLAR EPITHELIAL CELLS

**Sponsor:** NIH 1 K08 HL 094666 01

**Project Dates and Amount of Award:** 12/01/08-11/30/13; \$668,560

**PI:** Redman, Bruce

**Title:** UMCC 2008.039: AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL

**Sponsor:** Pfizer Incorporated TO INC Research, Inc

**Project Dates and Amount of Award:** 11/25/08-11/30/11; \$429,282

**PI:** Reisman, David

**Title:** UMCC 2007.126 A FEASIBILITY STUDY INVESTIGATING TRANSLATIONAL SCIENCE IN CHEMOTHERAPY-NAIVE PATIENTS



WITH STAGE IIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH THE EGFR-TKI, ERLOTINIB

**Sponsor:** NIH - Subcontracts TO Vanderbilt University

**Project Dates and Amount of Award:** 12/17/08-12/31/12; \$149,400

**PI:** Saran, Rajiv

**Co-I:** Gillespie, Brenda (Ctr Statistical Consul & Res) / Korgaonkar, Sonal (Int Med-Nephrology)

**Title:** ESTABLISHMENT OF A COLLABORATIVE FOR CLINICAL/ TRANSLATIONAL RESEARCH BETWEEN THE RENAL RESEARCH INSTITUTE (RRI) AND THE UM-KIDNEY EPIDEMIOLOGY AND COST CENTER (UM-KECC)

**Sponsor:** Renal Research Institute, LLC

**Project Dates and Amount of Award:** 08/01/08-07/31/09; \$190,000

**PI:** Worden, Francis

**Title:** UMCC 2008.063: CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS

**Sponsor:** Pfizer Incorporated TO INC Research, Inc

**Project Dates and Amount of Award:** 12/01/08-11/30/10; \$42,624

#### Medical School Administration Enabling Technologies

**PI:** Woolliscroft, James

**Co-I:** Engleberg, N (Int Med-Infectious Diseases) / Hanss Jr, Theodore (MSA Enabling Technologies)

**Title:** 2009 HEALTH OER DESIGN PHASE

**Sponsor:** Hewlett, William and Flora, Foundation, The

**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$500,000

#### Michigan Institute for Clinical and Health Research

**PI:** Clauw, Daniel

**Co-I:** Athey, Brian (Psychiatry-ASAP) / Bhavnani, Suresh (Computational Medicine and Bio)

**Title:** ADMINISTRATIVE SUPPLEMENT FOR CTSA CONSORTIUM PROJECT

**Sponsor:** NIH - Subcontracts TO University of Pittsburgh

**Project Dates and Amount of Award:** 09/15/08-06/30/09; \$75,000

#### Microbiology and Immunology

**PI:** Carruthers, Vernon

**Title:** PROTEOLYTIC MODULATION OF TOXOPLASMA INVASION PROTEINS

**Sponsor:** NIH 1 R01 AI 063263 01 A2

**Project Dates and Amount of Award:** 12/01/08-11/30/13; \$1,899,560

**PI:** Chang, Cheong-Hee

**Title:** IMMUNE REGULATION BY THYMOCYTE-SELECTED CD4 T CELLS

**Sponsor:** NIH 1 R01 AI 073677 01 A2

**Project Dates and Amount of Award:** 01/01/09-12/31/13; \$1,689,298

**PI:** Raghavan, Malini

**Co-I:** Pogozeva, Irina (College of Pharmacy) / Rizvi, Syed (Microbiology and Immunology)

**Title:** INTERACTIONS AND MECHANISMS OF FUNCTION OF THE TAP COMPLEX

**Sponsor:** NIH 2 R01 AI 044115 10 A2

**Project Dates and Amount of Award:** 01/01/09-12/31/13; \$1,705,540

#### Molecular & Behavioral Neuroscience Institute

**PI:** Umemori, Hisashi

**Title:** ACTIVITY-DEPENDENT SYNAPSE REFINEMENT IN THE HIPPOCAMPUS IN VIVO

**Sponsor:** Whitehall Foundation, Inc.

**Project Dates and Amount of Award:** 01/01/09-12/31/11; \$225,000

**PI:** Watson, Stanley

**Co-I:** Akil, Huda (Molecular & Behav Neurosc Inst) / Meng, Fan (Molecular & Behav Neurosc Inst) / Thompson, Robert (Psychiatry Department)

**Title:** COCAINE REGULATION OF MIRNAS IN RATS WITH DIFFERING VULNERABILITY TO DRUG ABUSE

**Sponsor:** NIH 1 R01 DA 025973 01

**Project Dates and Amount of Award:** 09/15/08-06/30/13; \$2,021,984

\* Corrected version of previous issue.

#### Neurology

**PI:** Brown, Devin

**Co-I:** Bapuraj, Jayapalli (Radiology Department)

**Title:** CARDIOVASCULAR RESONATOR

**Sponsor:** CVR Global, Inc.

**Project Dates and Amount of Award:** 12/12/08-12/11/09; \$231,253

**PI:** Irani, David

**Title:** LINKING INNATE IMMUNE RESPONSES IN THE CNS TO GLUTAMATE-MEDIATED EXCITOTOXICITY: STUDIES IN ACUTE ALPHAVIRUS ENCEPHALOMYELITIS IN MICE

**Sponsor:** Dana, Charles A. Foundation

**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$36,380

**PI:** Segal, Benjamin

**Title:** IMMUNE-GLIAL/ NEURONAL INTERACTIONS AND NEURODEGENERATION: IMPLICATIONS FOR AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM

**Sponsor:** Teva Neuroscience

**Project Dates and Amount of Award:** 03/01/09-08/31/09; \$68,965

#### Obstetrics & Gynecology

**PI:** Christman, Gregory

**Title:** COOPERATIVE MULTICENTER REPRODUCTIVE MEDICINE NETWORK

**Sponsor:** NIH - Subcontracts TO Yale University

**Project Dates and Amount of Award:** 12/01/08-11/30/09; \$66,702

#### Ophthalmology & Visual Sciences

**PI:** Cornblath, Wayne

**Title:** CASE-CROSSOVER STUDY OF PDE5 INHIBITOR EXPOSURE AS A POTENTIAL "TRIGGER FACTOR" FOR ACUTE NAION (A1481259)

**Sponsor:** Pfizer Incorporated TO ICON Clinical Research, Inc.

**Project Dates and Amount of Award:** 12/03/08-07/31/11; \$50,364

**PI:** Trobe, Jonathan

**Title:** PROTEOMICS AND GENOMICS OF GIANT CELL ARTERITIS (AGREEMENT BETWEEN UM AND UUTAH)

**Sponsor:** American Geriatrics Society TO University of Utah

**Project Dates and Amount of Award:** 10/22/08-10/21/09; \$2,000

#### Orthopaedic Surgery

**PI:** Goldstein, Steven

**Title:** BILE ACID CONJUGATES FOR IMPROVING THE ORAL BIOAVAILABILITY OF METHOTREXATE

**Sponsor:** NIH - Subcontracts TO TSRL R41 AR 055402

**Project Dates and Amount of Award:** 05/01/08-04/30/09; \$43,446

#### Otolaryngology

**PI:** Schacht, Jochen

**Title:** TESTING AMINOGLYCOSIDE DERIVATIVES FOR FREE-RADICAL TOXICITY TO HAIR CELLS IN ORGAN OF CORTI EXPLANTS

**Sponsor:** University of Zurich

**Project Dates and Amount of Award:** 09/01/08-12/31/09; \$12,000

#### Pathology

**PI:** Kunkel, Steven

**Co-I:** Hogaboam, Cory (Pathology Department)

**Title:** CYTOKINE PHENOTYPES ALTER THE HOST'S RESPONSE DURING CHRONIC LUNG INFLAMMATION

**Sponsor:** NIH 1 R01 HL 089216 01 A2

**Project Dates and Amount of Award:** 12/01/08-11/30/13; \$1,906,845

**PI:** Kunkel, Steven

**Co-I:** Dou, Yali (Pathology Department) / Standiford, Theodore (Int Med-Pulm./ Critical Care)

**Title:** MONOKINE GENE EXPRESSION/REGULATION IN LUNG INJURY

**Sponsor:** NIH 2 R01 HL 031237 24 A1

**Project Dates and Amount of Award:** 01/01/09-12/31/13; \$1,884,925

**PI:** Visscher, Daniel

**Co-I:** Kunju, Lakshmi (Pathology Department)

**Title:** MANUAL READ OF BREAST TISSUE H&E SLIDES, PERFORMANCE CHARACTERISTICS

**Sponsor:** Aperio Technologies, Inc.

**Project Dates and Amount of Award:** 11/11/08-03/11/09; \$23,820

#### Pediatrics & Communicable Diseases

**PI:** Collins, Katherine

**Title:** CHRONIC KIDNEY DISEASE IN CHILDREN PROSPECTIVE COHORT STUDY (CKID)

**Sponsor:** NIH - Subcontracts TO Johns Hopkins University U01 DK 066174

**Project Dates and Amount of Award:** 08/01/08-07/31/09; \$48,170

**PI:** Hinkovska-Galcheva, Vania

**Co-I:** Shanley, Thomas (Pediatrics-Intensive Care)

**Title:** ROLE OF CERAMIDE-1-PHOSPHATE/ CERAMIDE KINASE IN REGULATION OF CALCIUM SIGNALING DURING PHAGOCYTOSIS AND INFLAMMATION

**Sponsor:** American Heart Assoc, Inc.

**Project Dates and Amount of Award:** 01/01/09-12/31/12; \$308,000

**PI:** Nasr, Samya  
**Co-I:** Arteta, Manuel (Pediatrics-Pulmonary Medicine) / Filbrun, Amy (Pediatrics-Pulmonary Medicine) / Lumeng, Carey (Pediatrics-Pulmonary Medicine) / Tsai, Wan (Pediatrics-Pulmonary Medicine)  
**Title:** PANCRELIPASE DELAYED RELEASE CAPSULES IN INFANTS AND CHILDREN LESS THEN SEVEN YEARS OF AGE WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS (AN OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF)  
**Sponsor:** Solvay Pharmaceuticals, Inc. TO Quintiles, Inc.  
**Project Dates and Amount of Award:** 12/01/08-11/30/09; \$51,652

**PI:** Shanley, Thomas  
**Title:** ENSURING THE SAFETY AND COMFORT OF CRITICALLY ILL INFANTS AND CHILDREN  
**Sponsor:** NIH - Subcontracts TO University of Pennsylvania R01 HL 086622  
**Project Dates and Amount of Award:** 04/01/08-03/31/09; \$144,000

### Pharmacology

**PI:** Isom, Lori  
**Title:** FASEB SUMMER CONFERENCE ON ION CHANNEL REGULATION  
**Sponsor:** NIH 1 R13 NS 064810 01  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$20,000

**PI:** Svoboda, Laurie  
**Title:** REGULATION OF KV1.5 VIA REDOX-MEDIATED POSTTRANSLATIONAL MODIFICATION  
**Sponsor:** American Heart Association, Midwest Affiliate  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$52,000

### Physical Medicine & Rehabilitation

**PI:** Kirsch, Ned  
**Title:** INTEGRATING INSTRUMENTATION WITH CONTEXT-SENSITIVE TASK GUIDANCE  
**Sponsor:** Defense, Department of-Other-Subcontracts TO AT Sciences  
**Project Dates and Amount of Award:** 07/15/08-03/14/09; \$5,967

### Psychiatry

**PI:** Glass, Jennifer  
**Title:** REBOXETINE (PNU-165442G) TO IMPROVE COGNITIVE FUNCTION IN FIBROMYALGIA PATIENTS (A PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY ASSESSING THE ABILITY OF)  
**Sponsor:** Pfizer Incorporated TO INC Research, Inc  
**Project Dates and Amount of Award:** 11/26/08-12/31/09; \$133,863

**PI:** Neal, David  
**Title:** INTEGRATED CARE FOR MEDICAID CONSUMERS WITH BEHAVIORAL HEALTH CARE NEEDS  
**Sponsor:** Health and Human Services, Department of-Office of the Secretary-Subcontracts TO MI, State Of Community Health  
**Project Dates and Amount of Award:** 10/01/08-09/30/09; \$1,163,599

### Radiology

**PI:** Luker, Gary  
**Co-I:** Luker, Kathryn (Radiology Department)  
**Title:** MOLECULAR IMAGING OF CHEMOKINE RECEPTOR SIGNALING  
**Sponsor:** NIH 1 R01 CA 136553 01  
**Project Dates and Amount of Award:** 01/01/09-12/31/13; \$1,503,610

### Surgery

**PI:** Beer, David  
**Title:** A NOVEL COMPUTATIONAL FRAMEWORK FOR INDIVIDUALIZED CLINICAL DECISION-MAKING  
**Sponsor:** NIH - Subcontracts TO West Virginia University  
**Project Dates and Amount of Award:** 09/15/08-09/14/09; \$21,089

**PI:** Brown, David  
**Title:** MINIATURIZED IMPLANTABLE RENAL ASSIST DEVICE FOR TOTAL RENAL REPLACEMENT THERAPY  
**Sponsor:** NIH - Subcontracts TO University of California - San Francisco EB 008049  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$37,780

**PI:** Henke, Peter  
**Title:** VALIDATION OF VTE RISK TOOL IN HOSPITALIZED SURGICAL PATIENTS  
**Sponsor:** Sanofi-Aventis Pharmaceuticals  
**Project Dates and Amount of Award:** 11/01/08-10/31/09; \$109,500

**PI:** Mulholland, Michael  
**Title:** NEUROPEPTIDE REGULATION OF ENTEROPANCREATIC FUNCTION  
**Sponsor:** NIH 4 R37 DK 043225 19  
**Project Dates and Amount of Award:** 01/01/09-12/31/13; \$1,832,191

**PI:** Napolitano, Lena  
**Co-I:** Park, Pauline (General Surgery Section) / Pelletier, Shawn (General Surgery Section)  
**Title:** SAFETY AND EFFICACY OF THE EXTRACORPOREAL LIVER ASSIST DEVICE (ELAD) IN PATIENTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH)  
**Sponsor:** Vital Therapies, Inc. (VTI)  
**Project Dates and Amount of Award:** 12/18/08-11/30/09; \$107,500

## UMMS RESEARCH PUBLICATIONS

### Cell & Developmental Biology

Taleb M, Brandon CS, Lee FS, Lomax MI, Dillmann WH, Cunningham LL. Hsp70 inhibits aminoglycoside-induced hair cell death and is necessary for the protective effect of heat shock. *J Assoc Res Otolaryngol.* 2008 Sep; 9(3): 277-89.

### Dermatology

Rittié L, Kang S, Voorhees JJ, Fisher GJ. Induction of collagen by estradiol: difference between sun-protected and photodamaged human skin in vivo. *Arch Dermatol.* 2008 Sep; 144(9): 1129-40.

Rittié L, Perbal B. Enzymes used in molecular biology: a useful guide. *J Cell Commun Signal.* 2008 Jun; 2(1-2): 25-45.

### Family Medicine

Aikens JE, Perkins DW, Piette JD, Lipton B. Association between depression and concurrent Type 2 diabetes outcomes varies by diabetes regimen. *Diabet Med.* 2008 Nov; 25(11): 1324-9.

Bonow RO, Masoudi FA, Rumsfeld JS, Delong E, Estes NA 3rd, Goff DC Jr, Grady K, Green LA, Loth AR, Peterson ED, Piña IL, Radford MJ, Shahian DM; American College of Cardiology; American Heart Association Task Force on Performance Measures. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *J Am Coll Cardiol.* 2008 Dec 9; 52(24): 2113-7.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT IV, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(12): 3577-87.

Djuric Z, Bird CE, Furumoto-Dawson A, Rauscher GH, Ruffin MT 4th, Stowe RP, Tucker KL, Masi CM. Biomarkers of psychological stress in health disparities research. *The Open Biomarkers Journal.* 2008; 1: 7-19.

Djuric Z, Vanloon G, Radakovich K, Dilaura NM, Heilbrun LK, Sen A. Design of a mediterranean exchange list diet implemented by telephone counseling. *J Am Diet Assoc.* 2008 Dec; 108(12): 2059-65.

Li C, Simeone DM, Brenner DE, Anderson MA, Shedden KA, Ruffin MT, Lubman DM. Pancreatic Cancer Serum Detection Using a Lectin/Glyco-Antibody Array Method. *J Proteome Res.* 2008 Dec 11. (Epub ahead of print).

Ruffin MT IV, Creswell JW, Jimbo M, Fetters MD. Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: Findings from a triangulation mixed methods investigation. *J Community Health.* 2008 Dec 10. (Epub ahead of print).

Wang C, O'Neill SM, Rothrock N, Gramling R, Sen A, Acheson LS, Rubinstein WS, Nease DE Jr, Ruffin MT 4th; for the Family Healthware™ Impact Trial (FHITr) group. Comparison of risk perceptions and beliefs across common chronic diseases. *Prev Med.* 2008 Nov 25. (Epub ahead of print).

### Human Genetics

Brewer GJ, Althaus J. How reliable and robust are current biomarkers for copper status?—comments by Brewer and Althaus. *Br J Nutr.* 2008 Dec; 100(6): 1341-2; discussion 1343-4.

Brunetti-Pierrri N, Berg JS, Scaglia F, Belmont J, Bacino CA, Sahoo T, Lalani SR, Graham B, Lee B, Shinawi M, Shen J, Kang SH, Pursley A, Lotze T, Kennedy G, Lansky-Shafer S, Weaver C, Roeder ER, Grebe TA, Arnold GL, Hutchison T, Reimschisel T, Amato S, Geraghty MT, Innis JW, Obersztyrn E, Nowakowska B, Rosengren SS, Bader PI, Grange DK, Naqvi S, Garnica AD, Bernes SM, Fong CT, Summers A, Walters WD, Lupski JR, Stankiewicz P, Cheung SW, Patel A. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. *Nat Genet.* 2008 Dec; 40(12): 1466-71.



Douglas JA, Roy-Gagnon MH, Zhou C, Mitchell BD, Shuldiner AR, Chan HP, Helvie MA. Mammographic Breast Density--Evidence for Genetic Correlations with Established Breast Cancer Risk Factors. *Cancer Epidemiol Biomarkers Prev.* 2008 Nov 24. (Epub ahead of print).

Dyson G, Frikke-Schmidt R, Nordestgaard BG, Tybjeerg-Hansen A, Sing CF. Modifications to the Patient Rule-Induction Method that utilize non-additive combinations of genetic and environmental effects to define partitions that predict ischemic heart disease. *Genet Epidemiol.* 2008 Nov 21. (Epub ahead of print).

Jin N, Chow CY, Liu L, Zolov SN, Bronson R, Davisson M, Petersen JL, Zhang Y, Park S, Duex JE, Goldowitz D, Meisler MH, Weisman LS. VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P(2) in yeast and mouse. *EMBO J.* 2008 Nov 27. (Epub ahead of print).

Nasonkin IO, Potok MA, Camper SA. Cre-mediated recombination in pituitary somatotropes. *Genesis.* 2008 Nov 26. (Epub ahead of print).

Omenn GS, Aebersold R, Paik YK. 7(th) HUPO World Congress of Proteomics: Launching the Second Phase of the HUPO Plasma Proteome Project (PPP-2) 16-20 August 2008, Amsterdam, The Netherlands. *Proteomics.* 2008 Dec 3. (Epub ahead of print).

Ramachandran S, Rosenberg NA, Feldman MW, Wakeley J. Population differentiation and migration: coalescence times in a two-sex island model for autosomal and X-linked loci. *Theor Popul Biol.* 2008 Dec; 74(4): 291-301.

Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, Cho KR. Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations. *Neoplasia.* 2008 Dec; 10(12): 1362-72.

Schäfer T, Pütz M, Lienkamp S, Ganner A, Bergbreiter A, Ramachandran H, Gieloff V, Gerner M, Mattonet C, Czarnecki PG, Sayer JA, Otto EA, Hildebrandt F, Kramer-Zucker A, Walz G. Genetic and physical interaction between the NPHP5 and NPHP6 gene products. *Hum Mol Genet.* 2008 Dec 1; 17(23): 3655-62.

Sisson JC, Giordano TJ, Raymond VM, Doherty GM, Gruber SB. First Description of Parathyroid Disease in Multiple Endocrine Neoplasia 2A Syndrome. *Endocr Pathol.* 2008 Nov 25. (Epub ahead of print).

Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. *Blood.* 2008 Dec 3. (Epub ahead of print).

## Internal Medicine

### Infectious Diseases:

Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. *Am J Health Syst Pharm.* 2008; 65(23): 2237-2243.

### Microbiology and Immunology

Alamuri P, Eaton KA, Himpsl SD, Smith SN, Mobley HL. Vaccination with Proteus Toxic Agglutinin, a Hemolysin-Independent Cytotoxin In vivo, Protects against Proteus mirabilis Urinary Tract Infection. *Infect Immun.* 2008 Nov 24. (Epub ahead of print).

Basma H, Soto-Gutiérrez A, Yannam GR, Liu L, Ito R, Yamamoto T, Ellis E, Carson SD, Sato S, Chen Y, Muirhead D, Navarro-Álvarez N, Wong RJ, Roy-Chowdhury J, Platt JL, Mercer DF, Miller JD, Strom SC, Kobayashi N, Fox IJ. Differentiation and Transplantation of Human Embryonic Stem Cell-Derived Hepatocytes. *Gastroenterology.* 2008 Oct 29. (Epub ahead of print).

Cooper S, Shedden K, Vu-Phan D. Invariant mRNA and mitotic protein breakdown solves the Russian Doll problem of the cell cycle. *Cell Biol Int.* 2008 Oct 22. (Epub ahead of print).

Craig DH, Gayer CP, Schaubert KL, Wei Y, Li J, Laouar Y, Basson MD. Increased extracellular pressure enhances cancer cell integrin binding affinity through phosphorylation of  $\beta$ 1-integrin at threonine 788/789. *Am J Physiol Cell Physiol.* 2008 Nov 12. (Epub ahead of print).

Dalebroux ZD, Edwards RL, Swanson MS. SpoT governs Legionella pneumophila differentiation in host macrophages. *Mol Microbiol.* 2008 Nov 24. (Epub ahead of print).

Hagan EC, Mobley HL. Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic Escherichia coli for kidney infection. *Mol Microbiol.* 2008 Oct 30. (Epub ahead of print).

Jiang M, Abend JR, Johnson SF, Imperiale MJ. The role of polyomaviruses in human disease. *Virology.* 2008 Nov 6. (Epub ahead of print).

Jiang M, Abend JR, Tsai B, Imperiale MJ. Early Events during BK Virus Entry and Disassembly. *J Virol.* 2008 Nov 26. (Epub ahead of print).

Kittendorf JD, Sherman DH. The methymycin/pikromycin pathway: A model for metabolic diversity in natural product biosynthesis. *Bioorg Med Chem.* 2008 Nov 5. (Epub ahead of print).

Lopanik NB, Shields JA, Buchholz TJ, Rath CM, Hothersall J, Haygood MG, Håkansson K, Thomas CM, Sherman DH. In Vivo and In Vitro Trans-Acylation by BryP, the Putative Bryostatin Pathway Acyltransferase Derived from an Uncultured Marine Symbiont. *Chem Biol.* 2008 Nov; 15(11): 1175-86.

Luker KE, Gupta M, Luker GD. Imaging chemokine receptor dimerization with firefly luciferase complementation. *FASEB J.* 2008 Nov 10. (Epub ahead of print).

O'Malley HA, Shreiner AB, Chen GH, Huffnagle GB, Isom LL. Loss of Na(+) channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis. *Mol Cell Neurosci.* 2008 Nov 1. (Epub ahead of print).

Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. *PLoS Pathog.* 2008 Aug 22; 4(8): e1000131.

Tkaczyk ER, Tkaczyk AH, Katnik S, Ye JY, Luker KE, Luker GD, Myc A, Baker JR Jr, Norris TB. Extended cavity laser enhanced two-photon flow cytometry. *J Biomed Opt.* 2008 Jul-Aug; 13(4): 041319.

Tran M, Caldwell-McMillan M, Khalife W, Young VB. Streptococcus intermedius causing infective endocarditis and abscesses: a report of three cases and review of the literature. *BMC Infect Dis.* 2008 Nov 10; 8(1): 154.

Waheed AA, Ono A, Freed EO. Methods for the Study of HIV-1 Assembly. *Methods Mol Biol.* 2009; 485: 163-84.

Yamanouchi K, Zhou H, Roy-Chowdhury N, Macaluso F, Liu L, Yamamoto T, Yannam GR, Enke C, Solberg TD, Adelson AB, Platt JL, Fox IJ, Roy-Chowdhury J, Guha C. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. *Hepatology.* 2008 Aug 8. (Epub ahead of print).

## Neurosurgery

Gong Y, Xi G, Hu H, Gu Y, Huang F, Keep RF, Hua Y. Increase of brain thrombin activity after experimental intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 47-50.

Gong Y, Xi G, Wan S, Keep RF, Hua Y. Effects of aging on complement activation and neutrophil infiltration after intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 67-70.

He Y, Hua Y, Song S, Keep RF, Xi G. Induction of autophagy in the rat hippocampus and cultured neurons by iron. *Acta Neurochir.* 2008; 105 (Supplement): 29-32.

Hua Y, Keep RF, Hoff JT, Xi G. Deferoxamine therapy for intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 3-6.

Keep RF, Xiang J, Ennis SR, Andjelicovic A, Hua Y, Xi G, Hoff JT. Blood-brain barrier function after intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 73-77.

Kuroiwa T, Okauchi M, Hua Y, Schallert T, Keep RF, Xi G. Neurological deficits and brain edema after intracerebral hemorrhage in Mongolian gerbils. *Acta Neurochir.* 2008; 105 (Supplement): 127-130.

Lee JY, Huang DL, Keep R, Sagher O. Effect of electrical stimulation of the cervical spinal cord on blood flow following subarachnoid hemorrhage. *J Neurosurg.* 2008 Dec; 109(6): 1148-54.

Nakamura T, Kuroda Y, Okabe N, Shibuya S, Kawai N, Tamiya T, Xi G, Keep RF, Itano T, Nagao S. Radial glia marker expression following experimental intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 95-97.

Qin Z, Xi G, Keep RF, Silbergleit R, He Y, Hua Y. Hyperbaric oxygen for experimental intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 113-117.

Reddy SJ, Al-Holou WN, Leveque JC, La Marca F, Park P. Traumatic lateral spondylolysis of the lumbar spine with a unilateral locked facet: description of an unusual injury, probable mechanism, and management. *J Neurosurg Spine.* 2008 Dec; 9(6): 576-80.

Song S, Hua Y, Keep RF, Wang J, Xi G. Deferoxamine reduces brain swelling in a rat hippocampal intracerebral hemorrhage model. *Acta Neurochir.* 2008; 105 (Supplement): 13-18.

Wu J, Yang S, Xi G, Song S, Fu G, Keep RF, Hua Y. Microglial activation and brain injury after intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 59-65.

Yamashita S, Okauchi M, Hua Y, Liu W, Keep RF, Xi G. Metallothionein and brain injury after intracerebral hemorrhage. *Acta Neurochir.* 2008; 105 (Supplement): 37-40.

Zhou LF, Xi G, Chen X-C, Keep RF, Huang F-P, Hua Y, Lu YC, Muraszko KM. (Eds.) *Cerebral Hemorrhage 2007*. New York: Springer-Verlag/Wien; 2008. 239 p.

## Obstetrics & Gynecology

Couyoumjian CA, Treadwell MC, Barr M. Prenatal sonographic diagnosis of Nager acrofacial dysostosis with unilateral upper limb involvement. *Pernat Diagn* 2008; 28: 964-966.

Lewicky-Gaup C, Morgan DM, Chey WD, Muellerleile P, Fenner DE. Successful physical therapy for constipation related to puborectalis dyssynergia improves symptom severity and quality of life. *Dis Colon Rectum*. 2008 Nov; 51(11): 1686-91.

Lin CCJ, Clouser C, Peegel H, Menon B, Menon KMJ. The extracellular domain of luteinizing hormone receptor dictates its efficiency of maturation. *Biochemical and Biophysical Res Com* 2008; 377: 307-311.

## Ophthalmology & Visual Sciences

Dunn SP, Stark WJ, Stulting RD, Lass JH, Sugar A, Pavilack MA, Smith PW, Tanner JP, Dontchev M, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ. The Effect of ABO blood incompatibility on corneal transplant failure in conditions with low-risk of graft rejection. *Am J Ophthalmol* 2008. (Epub ahead of print).

Janz NK, Musch DC, Gillespie BW, Wren PA, Niziol LM. Evaluating clinical change and visual function concerns in drivers and non-drivers with glaucoma. *Invest Ophthalmol Vis Sci*. 2008. (Epub ahead of print).

Nyong'o OL, Del Monte MA. Childhood visual impairment: normal and abnormal visual function in the context of developmental disability. *Pediatr Clin North Am* 2008; 55(6): 1403-15.

Vine AK. Recent advances in haemostasis and thrombosis. *Retina* 2008. (Epub ahead of print).

Zadro-Lamoureux LA, Zacks DN, Baker AN, Zheng QD, Hauswirth WW, Tsilfidis C. XIAP protects photoreceptors from retinal detachment-induced apoptosis. *Invest Ophthalmol Vis Sci* 2008. (Epub ahead of print).

## Otolaryngology

Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG, Wolf GT, Carey TE, Bradford CR. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. *Arch Otolaryngol Head Neck Surg*. 2008; 134(4): 363-9.

Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. *J Clin Oncol*. 2008; 26(19): 3128-37.

Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JM, Pan Q, Carey TE, Bradford CR, Prince ME, Cordell KG, Kirkwood KL, D'Silva NJ. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. *Cancer Res*. 2008; 68(10): 3959-69.

Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. *Mol Cancer Ther*. 2008; 7(6): 1533-42.

Sikora MJ, Bauer JA, Verhaegen M, Belbin TJ, Prystowsky MB, Taylor JC, Brenner JC, Wang S, Soengas MS, Bradford CR, Carey TE. Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. *Cancer Biol Ther*. 2008; 7(5): 767-76.

Taleb M, Brandon CS, Lee FS, Lomax MI, Dillmann WH, Cunningham LL. Hsp70 inhibits aminoglycoside-induced hair cell death and is necessary for the protective effect of heat shock. *J Assoc Res Otolaryngol*. 2008 Sep; 9(3): 277-89.

Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. *J Clin Oncol*. 2008; 26(19): 3138-46.

## Pediatrics & Communicable Diseases

Barks JD. Technical aspects of starting a neonatal cooling program. *Clin Perinatol*. 2008 Dec; 35(4): 765-75.

Dempsey AF, Freed GL. Adolescent vaccination: if you build it, will they come? *J Adolesc Health*. 2008 Dec; 43(6): 523-4.

Donaldson LD, Wojtys EM. Extraarticular drilling for stable osteochondritis dissecans in the skeletally immature knee. *J Pediatr Orthop*. 2008 Dec; 28(8): 831-5.

Ferrara JL. Advances in the clinical management of GVHD. *Best Pract Res Clin Haematol* 2008 Dec; 21(4): 677-82.

Freed GL, Cowan AE, Clark SJ. Primary care physician perspectives on reimbursement for childhood immunizations. *Pediatrics*. 2008 Dec; 122(6): 1319-24.

Freed GL, Cowan AE, Gregory S, Clark SJ. Variation in provider vaccine purchase prices and payer reimbursement. *Pediatrics*. 2008 Dec; 122(6): 1325-31.

## Psychiatry

Burnette ML, Schneider R, Ilgen MA, Timko C. Women's past-year prostitution status and receipt of substance abuse treatment services. *Psychiatr Serv*. 2008 Dec; 59(12): 1458-61.

Ilgen MA, Zivin K, McCammon RJ, Valenstein M. Pain and suicidal thoughts, plans and attempts in the United States. *Gen Hosp Psychiatry*. 2008 Nov-Dec; 30(6): 521-7.

Kilbourne AM, Biswas K, Pirraglia PA, Sajatovic M, Williford WO, Bauer MS. Is the collaborative chronic care model effective for patients with bipolar disorder and co-occurring conditions? *J Affect Disord*. 2009 Jan; 112(1-3): 256-61.

Kilbourne AM, McCarthy JF, Himelhoch S, Welsh D, Hauser P, Blow FC. Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders. *Gen Hosp Psychiatry*. 2008 Nov-Dec; 30(6): 495-500.

Rafaeli E, Cranford JA, Green AS, Shrouf PE, Bolger N. The good and bad of relationships: how social hindrance and social support affect relationship feelings in daily life. *Pers Soc Psychol Bull*. 2008 Dec; 34(12): 1703-18.

Valenstein M, Kim HM, Ganoczy D, McCarthy JF, Zivin K, Austin KL, Hoggatt K, Eisenberg D, Piette JD, Blow FC, Olsson M. Higher-risk periods for suicide among VA patients receiving depression treatment: Prioritizing suicide prevention efforts. *J Affect Disord*. 2009 Jan; 112(1-3): 50-58.

Walton MA, Cunningham R, Chermack ST, Tripathi S, Weber J, Maio RF, Booth BM. Predictors of violence following Emergency Department visit for cocaine-related chest pain. *Drug Alcohol Depend*. 2009 Jan 1; 99(1-3): 79-88.

## Radiation Oncology

Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T, Bradford C, Mukherji SK, Eisbruch A. Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. *Int J Radiat Oncol Biol Phys*. 2008 Dec 1; 72(5): 1287-90.

Dai Y, Liu M, Tang W, DeSano J, Burstein E, Davis M, Pienta K, Lawrence T, Xu L. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. *Clin Cancer Res*. 2008 Dec 1; 14(23): 7701-10.

Hamstra DA, Lee KC, Moffat BA, Chenevert TL, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. *Transl Oncol*. 2008 Dec; 1(4): 187-94.

Jin JY, Ajlouni M, Kong FM, Ryu S, Chetty IJ, Movsas B. Utilize target motion to cover clinical target volume (ctv) - a novel and practical treatment planning approach to manage respiratory motion. *Radiother Oncol*. 2008 Dec; 89(3): 292-303.

Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. *Clin Cancer Res*. 2008 Nov 1; 14(21): 6744-50. Review.

Rehemtulla A. Neoplasia: the second decade. *Neoplasia*. 2008 Dec; 10(12): 1314-24.

Soto DE, Andridge RR, Taylor JM, McLaughlin PW, Sandler HM, Pan CC. Predicting biochemical failure and overall survival through intrathrapy PSA changes during definitive external beam radiotherapy. *Int J Radiat Oncol Biol Phys*. 2008 Dec 1; 72(5): 1408-15.

Spalding AC, Zeitlin BD, Wilder-Romans K, Davis ME, Nor JE, Lawrence TS, Ben-Josef E. Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells. *Transl Oncol*. 2008 Dec; 1(4): 195-201.

## Surgery

### General Surgery:

Franz MG, Robson MC, Steed DL, et al. Guidelines to aid healing of acute wounds by decreasing impediments of healing. *Wound Rep Regen*. 2008; 16: 723-748.

Lubman DM, Li C, Simeone DM, Brenner D, Anderson MA, Shedden KA, Ruffin M. Pancreatic Cancer Serum Detection Using A Lectin/Glyco-Antibody Array Method. *J Proteome Res*. 2008, (In press).

Wang L, Heidt DG, Lee CJ, Logsdon CD, Zhang L, Fearon ER, Ljungman ME, Simeone DM. Oncogenic function of ATDC (TRIM 29) in pancreatic cancer through Wnt pathway activation and b-catenin stabilization. *Cancer Cell*. 2008. (In press).



### **Pediatric Surgery:**

Feng Y, Sun X, Yang H, Teitelbaum DH. Dissociation of E-Cadherin and {beta}-catenin in a mouse model of total parenteral nutrition: A mechanism for the loss of epithelial cell proliferation and villus atrophy. *J Physiol*. 2008 Dec 8. (Epub ahead of print).

### **Urology**

Albertus DL, Seder CW, Chen G, Wang X, Hartojo W, Lin L, Silvers A, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Bigbee WL, Chinnaiyan AM, Beer DG. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. *J Thorac Oncol*. 2008 Nov; 3(11): 1236-44.

Bajaj S, Fink-Bennett D, Bloom DA. Intestinal malrotation in adult seen on hepatobiliary scintigraphy. *Clin Nucl Med*. 2008 Dec; 33(12): 861-3.

Chuang MT, Fu JS, Jang CJ, Chan CC, Ni PC, Lee CT. Simulation of long-range transport aerosols from the Asian Continent to Taiwan by a Southward Asian high-pressure system. *Sci Total Environ*. 2008 Nov 15; 406(1-2): 168-79.

Cohn JA, Englesbe MJ, Wolf JS Jr. Can urologic oncologists help expand the renal donor pool with "restored" kidneys? *Urol Oncol*. 2008 Nov-Dec; 26(6): 573-4.

Dai Y, Liu M, Tang W, DeSano J, Burstein E, Davis M, Pienta K, Lawrence T, Xu L. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. *Clin Cancer Res*. 2008 Dec 1; 14(23): 7701-10.

Gabr AH, Elsayed ER, Gdor Y, Roberts WW, Wolf JS Jr. Obesity and morbid obesity are associated with a greater conversion rate to open surgery for standard but not hand assisted laparoscopic radical nephrectomy. *J Urol*. 2008 Dec; 180(6): 2357-62; discussion 2362.

Gdor Y, Gabr AH, Faerber GJ, Roberts WW, Wolf JS Jr. Success of laser endoureterotomy of ureteral strictures associated with ureteral stones is related to stone impaction. *J Endourol*. 2008 Nov; 22(11): 2507-11.

Kennedy OD, Brennan O, Mahony NJ, Rackard SM, O'Brien FJ, Taylor D, Lee CT. Effects of high bone turnover on the biomechanical properties of the L3 vertebra in an ovine model of early stage osteoporosis. *Spine*. 2008 Nov 1; 33(23): 2518-23.

Kisilevsky BS, Hains SM, Brown CA, Lee CT, Cowperthwaite B, Stutzman SS, Swansburg ML, Lee K, Xie X, Huang H, Ye HH, Zhang K, Wang Z. Fetal sensitivity to properties of maternal speech and language. *Infant Behav Dev*. 2008 Dec 4. (Epub ahead of print).

Lee CT, Latini DM. Urinary diversion: evidence-based outcomes assessment and integration into patient decision-making. *BJU Int*. 2008 Nov; 102(9 Pt B): 1326-33.

Lee CT, Tsai WY, Tung YC, Tsau YK. Transient pseudohypoparathyroidism as a cause of late-onset hypocalcemia in neonates and infants. *J Formos Med Assoc*. 2008 Oct; 107(10): 806-10.

Lewicky-Gaup C, Wei JT, Delancey JO, Fenner DE, McGuire EJ, Morgan DM. The association of Incontinence Symptom Index scores with urethral function and support. *Am J Obstet Gynecol*. 2008 Oct 29. (Epub ahead of print).

McCormick BP, Frey G, Lee CT, Chun S, Sibthorp J, Gajic T, Stamatovic-Gajic B, Maksimovich M. Predicting transitory mood from physical activity level among people with severe mental illness in two cultures. *Int J Soc Psychiatry*. 2008 Nov; 54(6): 527-38.

Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in america. *Urol Clin North Am*. 2009 Feb; 36(1): 11-27.

Moyad MA. Vitamin D: a rapid review. *Urol Nurs*. 2008 Oct; 28(5): 343-9, 384; quiz 350. Review.

Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-Modality Therapy with Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial. *Int J Radiat Oncol Biol Phys*. 2008 Oct 30. (Epub ahead of print).

Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. *Transl Oncol*. 2008 Dec; 1(4): 158-64.

Schulte RT, Keller LM, Hiner MR, Ohl DA, Smith GD. Temporal decreases in sperm motility: which patients should have motility checked at both 1 and 2 hours after collection? *J Androl*. 2008 Sep-Oct; 29(5): 558-63.

Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. *J Urol*. 2008 Dec; 180(6): 2384-8; discussion 2388.

Stoffel JT, Morgan D, Dunn R, Hsu Y, Fenner D, Delancey J, McGuire EJ, Wei JT. Urinary Incontinence After Stress Incontinence Surgery: A Risk Factor for Depression. *Urology*. 2008 Oct 24. (Epub ahead of print).

Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS. Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer. *Jpn J Clin Oncol*. 2008 Oct 24. (Epub ahead of print).

Tai CM, Lee YC, Wu MS, Chang CY, Lee CT, Huang CK, Kuo HC, Lin JT. The Effect of Roux-en-Y Gastric Bypass on Gastroesophageal Reflux Disease in Morbidly Obese Chinese Patients. *Obes Surg*. 2008 Oct 15. (Epub ahead of print).

Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. *Science*. 2008 Nov 13. (Epub ahead of print).

Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. *Neoplasia*. 2008 Nov; 10(11): 1285-94.

Wallner LP, Sarma AV, Lieber MM, St Sauver JL, Jacobson DJ, McGree ME, Gowen ME, Jacobsen SJ. Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the olmsted county study. *Cancer Epidemiol Biomarkers Prev*. 2008 Dec; 17(12): 3588-92.

Woods Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, Dunn RL, Smith DC, Keller ET. Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. *J Interferon Cytokine Res*. 2008 Nov 17. (Epub ahead of print).

Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008 Sep 1; 72(1): 153-60.

Worzel WP, Yu J, Almal AA, Chinnaiyan AM. Applications of genetic programming in cancer research. *Int J Biochem Cell Biol*. 2009; 41(2): 405-13.

Wu A, Kunju LP, Cheng L, Shah RB. Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtypes. *Histopathology*. 2008 Nov; 53(5): 533-44.